Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

Scroll down and select country
MEBO TMAU TESTING CURRENTLY SUSPENDED INDEFINITELY

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Tuesday, January 31, 2017

Support the MEBO Mission : RESEARCH


SUPPORT MEBO's MISSION

RESEARCH

ON RARE DISEASE DAY

You can be involved without leaving your home!

As a registered not-for-Profit company in England and Wales since 2009, and a registered Public Charity in the United States since 2010, MEBO has done its best to raise awareness by being a participant, one way or another, in most of the government and private entities that have published information of TMAU, such as,

1. Organization Member of NORD, National Organization of Rare Disorders in the United States

2. MEBO Research UK is an Organization Member of EURORDIS, The Voice of Rare Disease Patients in Europe http://www.eurordis.org/about-eurordis

3. RARE CONNECT: Eurordis is an "Initiative Connecting Rare Disease Patients Globally". All sufferers around the world are welcome to join Trimethylaminuria Community of RareConnect. Some moderators of this site are MEBO Directors.

4. ORPHANET : MEBO Research, UK

Orphanet has a link to the UK Medical Research Council funded (£358,000 GBP, equivalent to 422K/Euros or 552K/USD) research project performed by Dr. Elizabeth Shephard for a "Therapy for the body and Breath malodour disorder Trimethylaminuria (TMAU).

5. GENETIC ALLIANCE MEBO Research UK

If MEBO directors in the US and the UK have been able to accomplish all this and more in only 8 years, imagine how much we could accomplish if more sufferers participated on the Rare Disease Day projects and events.
In addition to providing sufferers with the opportunity to do the MEBO TMAU Urine Test, MEBO has also supported research projects, such as the pre-clinical drug development for TMAU performed by Dr. Elizabeth Shephard as indicated in the Research Councils UK website, noting that, "Patient group MEBO [will have access] to the benefits of this research. (Click on the "Outcome" tab).

As promised in the MEBO Mission Statement, MEBO is not only focused on TMAU research and treatment, but is also very committed to the pursuit of research to identify other forms of odor conditions. Therefore, the MEBO Metabolomic Profiling Pilot Study was launched in Edmonton, Canada with Dr. David Wishart (PhD Yale, 1991) at the Wishart Lab, University of Alberta. It is a registered research project with the ClinicalTrials.gov, Trial NCT02683876. (See updates.)

Click to see Info Pack
If MEBO directors in the US and the UK have been able to accomplish all this and more in only 8 years, imagine how much we could accomplish if more sufferers participated on the Rare Disease Day projects and events. Please refer to the,

Rare Disease Day
Patient Involvement : Research
28 February 2017.

María

María de la Torre
Founder and Executive Director

A Public Charity
maria.delatorre@meboresearch.com
www.meboresearch.org
www.mebo.com.br/
MEBO's Blog (English)
El Blog de MEBO (español)
MEBO Brasil - Blog (Portuguese)

0 comments:

Post a Comment